PT  - JOURNAL ARTICLE
AU  - SUZUKI, KANAKO
AU  - SASADA, SHINSUKE
AU  - KIMURA, YURI
AU  - EMI, AKIKO
AU  - KADOYA, TAKAYUKI
AU  - OKADA, MORIHITO
TI  - Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer
AID  - 10.21873/anticanres.16104
DP  - 2022 Dec 01
TA  - Anticancer Research
PG  - 5945--5949
VI  - 42
IP  - 12
4099  - http://ar.iiarjournals.org/content/42/12/5945.short
4100  - http://ar.iiarjournals.org/content/42/12/5945.full
SO  - Anticancer Res2022 Dec 01; 42
AB  - Background/Aim: Docetaxel and cyclophosphamide (TC) combination therapy is widely used as adjuvant chemotherapy for early-stage breast cancer and is associated with a high incidence of febrile neutropenia (FN). Granulocyte colony-stimulating factor (G-CSF) is recommended in the primary prevention of febrile neutropenia (FN). This study aimed to evaluate the FN-suppressing effect of G-CSF in patients with breast cancer receiving TC. Patients and Methods: We performed 272 treatment cycles after FN onset in 106 patients with breast cancer receiving TC. We retrospectively evaluated the effect of G-CSF as secondary prophylaxis. The frequency of FN was calculated based on the treatment cycles to adjust for differences in the number of cycles per case and FN occurrence. Results: FN occurred in 58 cycles (21.3%). The incidence of FN with and without secondary prophylactic G-CSF was 10.1% and 25.9%, respectively (p=0.003). Multivariate analysis showed secondary prophylactic G-CSF administration to be an independent predictor of FN incidence [odds ratio (OR)=0.33, 95% confidence interval (CI)=0.14-0.74, p=0.007]. Conclusion: Secondary prophylaxis with G-CSF is recommended for patients with breast cancer undergoing TC chemotherapy to reduce the incidence of FN.